NCT03852849

Rapid Build of HIV Related Protective Barriers

Cohort Study on Appropriate Strategies of The Rapid Build of HIV Related Protective Barriers in Yunnan, China

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 600 (estimated)
• Sponsor: National Center for AIDS/STD Control and Prevention, China CDC · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to screen the optimal intervention strategies to rapid establish the protective barriers against HIV-infection by maximally decreasing the viremia among HIV- infected patients.

Detailed description

Sexual transmission became the primary route of HIV transmission in China and heterosexual transmission also contributed greatly to HIV epidemic which was mostly reported in South-west rural areas. In past years, Yunnan has experienced powerful campaign of scaling-up the HIV identification as well as antrertroviral therapy. This study will investigate how to reach the last two of HIV'90-90-90 targets': to provide antiretroviral therapy (ART) for 90% of who diagnosed HIV infection and to achieve viral suppression for 90% of those treated. The study population consists of participants who received an newly diagnosed HIV infection within the study period. All rerolled participants will be randomized into different study group. In intervention group, medical institutions will provide patients personal involved intervention strategies which guided by frequent viral load detection, and providing of the dosage form of 400 mg EFV in their antiviral therapy. Main assessment measures are viral suppression rate of HIV-infected patients and treatment coverage .

Conditions

• Viral Suppression of HIV Infection

Interventions

Type	Name	Description
BEHAVIORAL	Personal involved intervention strategies	Medical institutions will provide personal involved intervention strategies for patients which guided by viral load testing monthly until viral load drop below the detection limit.
DRUG	The dosage of 400mg EFV	The dosage of 400mg EFV will be used in the antiviral therapy.

Timeline

• Start date: 2019-03-01
• Primary completion: 2020-12-31
• Completion: 2021-03-01
• First posted: 2019-02-25
• Last updated: 2019-02-25

Locations

2 sites across 1 country: China